BeyondSpring Inc develops breakthrough therapy Plinabulin, for chemotherapy-induced neutropenia indication for patients with cancer.
Plinabulin is a first-in-class differentiated immune and stem cell modulator. The complementary mechanisms actions of Plinabulin and G-CSFs can prevent chemotherapy-induced neutropenia.
U.S. Food and Drug Administration (FDA) and China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designations for Plinabulin in Prevention of Chemotherapy-Induced Neutropenia (CIN).
Chemotherapy-Induced Neutropenia (CIN) a common side effect is generally observed in cancer patients who are under treatment. CIN mainly destroys a type of white blood cells in a patient’s body which is considered to be the first line of defense against infections. Neutrophil, a type of white blood cell assures the patients from protecting against infectious diseases. Moreover, patients having low concentration of neutrophils may easily lead to infections, hospitalisation and death.
